24 noviembre 2013

Bayer's EYLEA Approved in Japan for Macular Endema Treatment . Post by Celtia .

(Reuters) - Bayer HealthCare has received approval from Japan's Ministry of Health to treat macular edema secondary to central retinal vein occlusion (CRVO) with its Eylea eye medication, the company said on Friday.

"The additional approval of Eylea in Japan for the treatment of macular edema secondary to CRVO is great news for patients in Japan suffering from this potentially sight-threatening eye condition," said Kemal Malik, member of the Bayer HealthCare Executive Committee and head of global development.

...